@FierceMedDev: The CFO of troubled Mela Sciences resigned on Dec. 31. CEO Rose Crane is filling in. Release | Follow @FierceMedDev
@MichaelGFierce: Gene therapy technique from Washington University in St. Louis targets tumor blood vessels. Article | Follow @MichaelGFierce
@GalenMoore: Drug companies accused of holding back complete information on clinical trials. Story | Follow @GalenMoore
> InVivo Therapeutics ($NVIV) secured FDA approval to kick off its first clinical trial for an in-development spinal scaffold. Article
> IMS Health, which provides prescription and procedure data to drug and medical device companies, has filed for a $100 million IPO. News
> In its nearly 20 years in business, Luminex ($LMNX) has risen from small-staffed specialist to a heavyweight in diagnostics. Story
Biotech News
@FierceBiotech: Marina Biotech, Mirna Therapeutics amend license deal to develop microRNA-based therapeutics. Release | Follow @FierceBiotech
@JohnCFierce: Top FierceBiotech story yesterday: Is it human, animal or plant? At Bayer, they're mixing all three in new R&D recipe. More | Follow @JohnCFierce
@DamianFierce: The long, strange trip that was Wright Medical's 2013. Report | Follow @DamianFierce
@EmilyMFierce: Cancer Research UK to repurpose an AstraZeneca asthma drug for kidney cancer. Story from FierceBiotech Research | Follow @EmilyMFierce
> Ambitious HDL program joins a growing list of high-profile clinical failures. Story
> A step ahead of controversial transparency rules, Sanofi commits to open access. Report
> NeXeption raises $21.5M to launch dermatology startup Alexar. Article
Pharma News
@FiercePharma: Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets. Release | Follow @FiercePharma
@EricPFierce: Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M. More | Follow @EricPFierce
@CarlyHFierce: Cue more drama in Teva's boardroom as its CEO announcement nears. Yesterday's story | Follow @CarlyHFierce
> Bayer's hot-selling Eylea runs into a roadblock in its home market. Story
> Mylan has hired away a new India president from Biocon, its partner there. Report
> China clears hep B vaccine makers in child deaths. More